Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


Pluristem Files for Orphan Drug Status with U.S. FDA for Use of PLX Cells in Treatment of Aplastic Anemia 

 

 

Pluristem Files for Orphan Drug Status with U.S. FDA for Use of PLX Cells in Treatment of Aplastic Anemia

August 30, 2012 - (Pluristem) -"Pluristem Therapeutics, Inc. a leading developer of placenta-based cell therapies, today announced that it has filed the necessary documents requesting that the U.S. Food and Drug Administration (FDA) grant orphan drug status to its PLacental eXpanded (PLX) cells for the treatment of aplastic anemia."  Read Full Article

 

Posted on 6-Sep-12 by Toto, Brent
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: